TaiRx’s CVM-1118 small molecule cancer drug received US FDA approval on April 15th to conduct multi-nation, multi-center Phase II clinical trial in the US and Taiwan. The trial will be conducted in combination with Nexavar® for hepatocellular carcinoma patients. This approval has once again proved that Taiwan’s innovation and research and development capability to be on par with the global standard. According market analysis from Market Data Forecast, the global market for hepatocellular carcinoma treatment drug has reached 570 million USD in 2016 and is projected to grow at an yearly compound growth rate of 9.1% reaching 880 million USD in 2021.
CVM-1118 is the innovative result of Taiwan academia and industry collaboration. It not only has outstanding therapeutic effect and superior safety margin, but also possesses multiple mechanisms of actions and unique anti-VM inhibition which can prevent tumor cell metastasis. There are currently no similar drug on the global market.
TaiRx will continue its effort to innovate and focus on the health and well-being of the human race.